RavasioR.; AntonelliS.; MaiorinoA.; CostanzoA.; LosiS. Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Global & Regional Health Technology Assessment, v. 6, n. 1, 7 jan. 2019.